drugset / Trial / NCT00475956
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to determine if the maximum tolerated doses of AZD2171, in combination with AZD0530, in treating patients with advanced solid tumours are safe, tolerable and efficacious.
Timeline
- Start
- 2007-05
- Primary completion
- 2008-10
- Completion
- 2009-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cediranib | Small molecule | 20 mg | Oral |
| Subject | Cediranib | Small molecule | 30 mg | Oral |
| Subject | Cediranib | Small molecule | 45 mg | Oral |
| Subject | saracatinib | Small molecule | 125 mg | Oral |
| Subject | saracatinib | Small molecule | 175 mg | Oral |